Taiwan Bio Therapeutics Co., Ltd

NT$25.75As of Sun 8 Nov 2026, 12:00 UTC

TPEx:6892Healthcare

Country Taiwan

PE (Fwd) —

TSR 4Y CAGR (0.32%)

Div yield —

ROE (41.92%)

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM (14.17%)

Mkt cap NT$2.385B

ROIC (51.66%)

SE Grade™

—

Value

Quality

Moat

1Y Price

Reference

NT$27

3.33%

(81.12%)

Price above Reference Value

TTM

FYE 31 Dec TWD

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

50.43

RevenueNT$M

—

44.74

85.47

105.1

50.43

55.09

4.06%

—

(52.02)

Revenue growth%

—

91.02

22.96

(52.02)

9.25

22.96

—

63.74

Gross margin%

—

70.77

89.34

53.35

63.74

64.90

67.25

—

(762.04)

Operating margin%

—

(417.14)

(251.08)

(334.41)

(762.04)

(100.00)

(375.78)

—

(756.85)

Net margin%

—

(421.41)

(254.49)

(334.75)

(756.85)

(100.00)

(378.08)

—

P/E ratio (avg)x

—

EV/EBITx

—

(11.22)

FCF yield (avg)%

—

(15.17)

(13.55)

(11.42)

(9.18)

(2.53)

(12.49)

—

(484.70)

FCF margin%

—

(498.74)

(334.37)

(345.65)

(484.70)

(100.00)

(415.18)

—

0.640

FCF / Net incomex

—

1.183

1.314

1.033

0.640

—

1.108

—

(51.66)

ROIC%

—

(32.89)

(35.73)

(51.55)

(51.66)

(7.27)

(43.64)

—

(41.92)

Return on equity%

—

(35.79)

(38.16)

(41.27)

(41.92)

(7.85)

(39.72)

—

(28.17)

Return on assets%

—

(21.65)

(23.10)

(23.90)

(28.17)

(4.24)

(23.50)

—

(4.51)

EPSNT$

—

(3.78)

(3.79)

(4.81)

(4.51)

(0.65)

—

6.21

EPS growth%

—

(0.38)

(26.87)

6.21

85.57

(0.38)

—

8.63

Bookvalue per shNT$

—

10.56

10.69

14.93

8.63

7.98

(6.50%)

—

(2.89)

FCF per shareNT$

—

(4.47)

(4.98)

(4.97)

(2.89)

(0.65)

—

Dividend per shNT$

—

Div yield (avg)%

—

Payout ratio%

—

92.61

Shares (diluted)M

—

49.91

57.35

73.11

84.56

◌84.56

19.22%

—

(15.67)

Buyback yield%

—

(14.91)

(27.48)

(15.67)

◌—

(15.67)

—

0.437

D/E ratiox

—

0.544

0.438

0.290

0.437

0.473

0.437

—

2.413

Enterprise valueNT$B

—

1.512

2.129

2.819

2.691

2.261

21.19%

—

LT debtNT$M

—

Peers (US$62.35M)

Cap (US$)

Syngen Biotech Co.,Ltd.

65.73M

10.65x

HeXun Biosciences Co.…

63.14M

15.91x

3D Global Biotech Inc.

59.75M

139.8x

Poolbeg Pharma PLC

62.15M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(54.23)

(47.33)

Own earn%

—

Sh yield%

(15.67)

Owners

Insiders/Inst%

14.47

7.31

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

2/3

EPS growth years

1/3

Dividend streakyrs

Op margin range%

−762–−251

$1 testx

—

Incr. ROIC%

−104

Taiwan Bio Therapeutics Co., Ltd., regenerative medicine company, focuses on the development of new cell medicines. It offers medicines for degenerative diseases, cardiovascular diseases, diabetes complications, and autoimmune diseases. The company was founded in 2014 and is based in Taipei, Taiwan.

Growth vs revenue

Latest

Trend

3Y CAGR

Rel growth

Revenue

NT$50.43M

4.06%

1.00×

Cost of revenue

NT$18.29M

11.82%

1.24×

Operating expenses

NT$416.4M

24.02%

1.69×

Asset mix

Trend

Other

78.56%

Cash and investments

21.44%

Reinvestment returns

No breakdown available